PT1356046E - Receptor de citocina zcytor19 - Google Patents

Receptor de citocina zcytor19 Download PDF

Info

Publication number
PT1356046E
PT1356046E PT01988203T PT01988203T PT1356046E PT 1356046 E PT1356046 E PT 1356046E PT 01988203 T PT01988203 T PT 01988203T PT 01988203 T PT01988203 T PT 01988203T PT 1356046 E PT1356046 E PT 1356046E
Authority
PT
Portugal
Prior art keywords
european patent
grant
date
epc
epo
Prior art date
Application number
PT01988203T
Other languages
English (en)
Inventor
Francis J Grant
Theodore E Whitmore
Scott R Presnell
Wenfeng Xu
Julia E Novak
Original Assignee
Zymogenetics L L C
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics L L C, Bristol Myers Squibb Co filed Critical Zymogenetics L L C
Publication of PT1356046E publication Critical patent/PT1356046E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)

Description

DESCRIÇÃO

Claims (1)

  1. REIVINDICAÇÕES
    Europãisches Patentamt European Patent Office Office européen des brevets European Patent Office 80298 MUNICH GERMANY Tel. +49 (0)89 2399 - 0 Fax +49(0)89 2399 - 4465 MacLean, Martin Robert Mathys & Squire LLP 120 Holborn London EC1N2SQ GRANDE BRETAGNE For any questions about this communication: Tel.:+31 (0)70 340 45 00 Date 17.09.09 Reference Application No./Patent No. P25666EP-PCT 01988203.4-2401 /1356046 Applioant/Proprietor ZymoGenetics, L.L.C., et ai Decision to grant a European patent pursuant to Article 97(1) EPC Following examination of European patent application No. 01988203.4 a European patent with the title and the supporting documents indicated in the communication pursuant to Rule 71(3) EPC dated 04.02.09 is hereby granted in respect of the designated Contracting States. The requestfor amendments received at the EPO on 02.06.09 and any subsequent modifications agreed with the applicant have been taken into account. Patent No. Date of filing Priority claimed 1356046 28.11.01 28.11.00/USP 253561 07.02.01/USP 267211 Designated Contracting States and Proprietor(s) : AT BE CH CY DE DK ES Fl FR GB GR ΙΕ IT LI LU MC NL PT SE TR ZymoGenetics, L.L.C. 1201 Eastlake Avenue East Seattle, WA 98102/US AT BE CH CY DE DK ES Fl FR GB GR IE IT LI LU MC NL PT SE TR Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08540/US This decision will take effect on the date on which the European Patent Bulletin mentions the grant (Art. 97(3) EPC). The mention of the grant will be published in European Patent Bulletin 09/42 of 14.10.09. to EPO postal service: 11.09.09 Registered letter EPO Form 2006A 12.07 11.09.09
PT01988203T 2000-11-28 2001-11-28 Receptor de citocina zcytor19 PT1356046E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25356100P 2000-11-28 2000-11-28
US26721101P 2001-02-07 2001-02-07

Publications (1)

Publication Number Publication Date
PT1356046E true PT1356046E (pt) 2010-03-09

Family

ID=26943370

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01988203T PT1356046E (pt) 2000-11-28 2001-11-28 Receptor de citocina zcytor19

Country Status (12)

Country Link
US (10) US20030027253A1 (pt)
EP (1) EP1356046B1 (pt)
JP (1) JP2004532611A (pt)
AT (1) ATE445701T1 (pt)
AU (1) AU2002241533A1 (pt)
CA (1) CA2430485A1 (pt)
CY (1) CY1110921T1 (pt)
DE (1) DE60140213D1 (pt)
DK (1) DK1356046T3 (pt)
ES (1) ES2334888T3 (pt)
PT (1) PT1356046E (pt)
WO (1) WO2002044209A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532611A (ja) * 2000-11-28 2004-10-28 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１９
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
JP4409962B2 (ja) * 2002-04-19 2010-02-03 ザイモジェネティクス，インコーポレイティド サイトカイン受容体
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
DK1668031T3 (da) 2003-08-07 2008-06-30 Zymogenetics Inc Homogene præparater af IL-29
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
US7351689B2 (en) 2004-07-29 2008-04-01 Zymogenetics, Inc. Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
RU2518483C2 (ru) 2007-01-31 2014-06-10 Биал-Портела Энд Ка, С.А. Режим дозирования ингибиторов комт
MX2010004892A (es) * 2007-10-31 2010-08-10 Scripps Research Inst Terapia de combinacion para tratar infecciones virales persistentes.
ES2915698T3 (es) * 2009-04-01 2022-06-24 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas
DK2413912T3 (da) 2009-04-01 2019-06-17 Bial Portela & Ca Sa Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CN103732610A (zh) * 2011-06-13 2014-04-16 默沙东公司 纯化天然或突变体形式的白喉毒素的方法
PL2791134T3 (pl) 2011-12-13 2020-03-31 BIAL - PORTELA & Cª S.A. Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy
BR112015023520A2 (pt) * 2013-03-15 2017-10-24 Abbvie Inc purificação do conjugado de anticorpo-fármaco (adc)
TW201446961A (zh) * 2013-05-06 2014-12-16 Abbvie Inc 用於細胞培養之組合物及其使用方法
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
EP3442567A4 (en) * 2016-04-13 2019-12-18 Orimabs Ltd. ANTI-PSMA ANTIBODIES AND THEIR USE
WO2023049774A1 (en) * 2021-09-21 2023-03-30 University Of Washington Genetically encoded and exogenously triggered protein-protein ligation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU6069300A (en) 1999-07-02 2001-01-22 Chiron Corporation Novel human genes and gene expression products
JP2004509617A (ja) * 2000-09-08 2004-04-02 シェーリング　コーポレイション 哺乳動物遺伝子；関連試薬および方法
JP2004532611A (ja) 2000-11-28 2004-10-28 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１９
CN100482684C (zh) * 2001-04-20 2009-04-29 津莫吉尼蒂克斯公司 细胞因子蛋白质家族
EP1439223A1 (en) 2001-10-02 2004-07-21 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
AU2003215136A1 (en) 2002-02-08 2003-09-02 University Of Medicine And Dentistry Of New Jersey Ifn-a/b-independent mechanism of antiviral protection
JP4409962B2 (ja) 2002-04-19 2010-02-03 ザイモジェネティクス，インコーポレイティド サイトカイン受容体
JP2006509041A (ja) 2002-10-23 2006-03-16 ザイモジェネティクス，インコーポレイティド Ｉｌ−２８およびｉｌ−２９を用いるウイルス感染を治療するための方法
JP2009520459A (ja) 2003-02-14 2009-05-28 サイグレス ディスカバリー， インコーポレイテッド 癌における治療標的

Also Published As

Publication number Publication date
AU2002241533A1 (en) 2002-06-11
DE60140213D1 (de) 2009-11-26
US20070048846A1 (en) 2007-03-01
JP2004532611A (ja) 2004-10-28
EP1356046A2 (en) 2003-10-29
US20030027253A1 (en) 2003-02-06
US7608452B2 (en) 2009-10-27
US7601809B2 (en) 2009-10-13
DK1356046T3 (da) 2010-03-01
US20070111942A1 (en) 2007-05-17
US20110091876A1 (en) 2011-04-21
ES2334888T3 (es) 2010-03-17
WO2002044209A2 (en) 2002-06-06
EP1356046B1 (en) 2009-10-14
US20070048804A1 (en) 2007-03-01
ATE445701T1 (de) 2009-10-15
US20050266485A1 (en) 2005-12-01
US7618791B2 (en) 2009-11-17
CY1110921T1 (el) 2015-06-10
US20140248661A1 (en) 2014-09-04
CA2430485A1 (en) 2002-06-06
US20070117165A1 (en) 2007-05-24
US20070048799A1 (en) 2007-03-01
WO2002044209A3 (en) 2003-08-21
US20120064571A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
PT1356046E (pt) Receptor de citocina zcytor19
Emilie et al. Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients
Coleman et al. Regulation of mouse peritoneal mast cell secretory function by stem cell factor, IL-3 or IL-4.
Gaidano et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen
McKinstry et al. Cytokine receptor expression on hematopoietic stem and progenitor cells
Naidu et al. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma.
Soejima et al. A functional IFN-γ-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan
Lüttichau et al. A highly selective CC chemokine receptor (CCR) 8 antagonist encoded by the poxvirus molluscum contagiosum
Rose et al. Oncostatin M (OSM) inhibits the differentiation of pluripotent embryonic stem cells in vitro
Phipps et al. Fibroblast heterogeneity in the periodontium and other tissues
Jostock et al. Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Müllberg et al. IL-6 receptor independent stimulation of human gp130 by viral IL-6
Kollet et al. The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34+ CD38−/low cells capable of repopulating severe combined immunodeficiency mice
Lee et al. Induction of interleukin 2 receptor (TAC) by tumor necrosis factor in YT cells.
Tweardy et al. Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells
Andjelkovic et al. Expression of binding sites for β chemokines on human astrocytes
Hoischen et al. Human herpes virus 8 interleukin‐6 homologue triggers gp130 on neuronal and hematopoietic cells
Drexler et al. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells
EP1555318A3 (en) Hematopoietic cytokine receptor
WO2002000721A8 (en) Cytokine receptor zcytor17
NZ510744A (en) Cytokine receptor zalpha11
Gruss et al. Hodgkin's Disease: A Cytokine-Producing Tumor− A Review
Ruiz et al. CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T‐cell lymphoma
Reya et al. Regulated expression and function of CD122 (interleukin-2/interleukin-15R-beta) during lymphoid development
Allavena et al. Migratory response of human NK cells to monocyte-chemotactic proteins